Norway Oligonucleotide Therapeutics Market Size & Outlook

Name: Norway Oligonucleotide Therapeutics Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The oligonucleotide therapeutics market in Norway is expected to reach a projected revenue of US$ 326.5 million by 2033. A compound annual growth rate of 19.1% is expected of Norway oligonucleotide therapeutics market from 2026 to 2033.

Norway oligonucleotide therapeutics oligonucleotide class outlook (Revenue, USD million, 2021-2033)
- Antisense Oligonucleotides (ASOs)
- Small Interfering RNA (siRNA)
- Aptamers
- microRNA (miRNA)
- CpG Oligonucleotides
- Other Oligonucleotide Therapeutics
Norway oligonucleotide therapeutics therapeutic area outlook (Revenue, USD million, 2021-2033)
- Neurology
- Oncology
- Cardiometabolic Disorders
- Infectious Diseases
- Ophthalmology
- Other Therapeutic Areas
Norway oligonucleotide therapeutics route of administration outlook (Revenue, USD million, 2021-2033)
- Subcutaneous
- Intravenous
- Intrathecal
- Intramuscular
- Other Routes

Norway Oligonucleotide Therapeutics Market Size & Outlook

Sign up - it's easy, and free!